Walleye Capital
ANTX icon

Walleye Capital’s AN2 Therapeutics ANTX Stock Holding History

Walleye Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-92,406
Closed -$199K – 5233
2024
Q2 		$199K Sell
92,406
-40,381
-30% -$96.1K ﹤0.01% 4306
2024
Q1 		$432K Buy
+132,787
New +$1.44M ﹤0.01% 3327

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's ANTX Position: Q3 2024 in Review

Walleye Capital sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 92,406 shares — an estimated $199K sold.

Walleye Capital first reported a position in ANTX in Q1 2024 and held it in 2 quarters. The position peaked at $432K in Q1 2024. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Walleye Capital reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 92,406 AN2 Therapeutics shares in Q3 2024, an estimated $199K.
  • Walleye Capital first reported a position in AN2 Therapeutics in Q1 2024 and held it in 2 quarters.
  • Walleye Capital's AN2 Therapeutics position peaked at $432K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.